Fungal infections, particularly invasive aspergillosis (IA), stil

Fungal infections, particularly invasive aspergillosis (IA), still present a diagnostic and therapeutic dilemma for the physicians who take care of the patients with severe underlying diseases and immunosuppression. Because the severity of the underlying disease,

critical illness and acute conditions preclude the diagnosis most of the time, empirical antifungal treatment has been the mainstay of management of such patients until recently. Empirical approach has its own disadvantages including unnecessary exposure to toxic effects and drug interactions as well as increased cost. However, the search for an ideal diagnostic marker, which can guide pre-emptive RXDX-106 mouse therapy, has been inconclusive so far.1 The accuracy of the microbiological methods in diagnosing IA depends on the type of the specimen obtained. Tissue biopsies are the best as culture specimens, because histopathological SB525334 confirmation can be done simultaneously. However, the critical illness of the patients usually does not allow an invasive procedure.2 Imaging modalities such as high resolution computed tomography (CT) are non-invasive options for diagnosing Aspergillus infections.3–5 Serial tomograms starting on the early days of the febrile neutropenic period are required to detect the halo sign that

suggests IA in the appropriate host and setting.6,7 Galactomannan (GM), which is a polysaccharide cell-wall component of Aspergillus, is a promising molecule to search for the clues of Aspergillus infection and tissue invasion.8 Methods like enzyme immunoassay, radioimmunoassay and latex agglutination have been used to identify GM in different specimens.9,10 Commercial kits (Platelia®Aspergillus; Bio-Rad Laboratories, Marnes-la-Coquette,

France) that use the monoclonal anti-GM antibody EB-A2 as both capture and peroxidase-linked antibodies in sandwich enzyme-linked immunosorbent assay (ELISA) are available.10,11 While the specificity of the test is quite high, reported sensitivities in different studies display wide variations.9,12–20 The dispute about the ideal cut-off point was a subject of matter Dolutegravir purchase as well as the reproducibility of the test. Recently, an index cut-off of 0.5 was accepted in Europe after the study by Maertens and colleagues.12,14,21–26 In this study, we aimed to evaluate the diagnostic accuracy of serial GM measurements in our high-risk patients along with the possible caveats in diagnosing and treating IA in our centre, and focused on the possible ways to use the method more effectively in our routine clinical practice in the future. This prospective cohort study was carried out in Hacettepe University Hospital for Adults. The study was approved by the ethics committee of the Faculty of Medicine (Approval date 12 July 2001, HEK 01/30-4).

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>